| | | | Venetoclax | | | Royal Melbourne | Hospital Peter MacCallum | Cancer Cente | Venetoclax Bcl-2 Bcl-2 | | 4 | 116 | 79% | CLL | 20% | | Venetoclax | FDA | | | | | | | | |